The ITC's decision to invalidate US Synthetics' patent claims under 35 U.S.C. § 101 represents an alarming shift towards using abstract idea analysis against physical composition claims. It raises concerns about how far this doctrine can reach, especially when longstanding patent principles suggest that compositions of matter should generally be seen as non-abstract. The involvement of PhRMA emphasizes the necessity of preserving patent rights in tangible inventions and ensuring they aren't swept away under overly broad interpretations of the law.
In a landmark October 2022 ruling, the ITC invalidated claims for US Synthetics' polycrystalline diamond compact patents, signaling a troubling precedent that may pose risks to the entire patent ecosystem. PhRMA’s amicus brief underscored the vital distinction between traditional compositions of matter and less tangible inventions, like software. They argue that allowing abstract idea analysis to extend to tangible items could lead to further erosion of patent protections, ultimately stifling innovation rather than promoting it.
Collection
[
|
...
]